Rocuronium bromide

[3- hydroxy-10 ,13- dimethyl-2- morpholin-4 -yl -16 -(1- prop-2- enyl -2 ,3,4,5- tetrahydropyrrol -1-yl ) - 2,3,4, 5,6,7,8,9,11,12,14,15,16,17 - tetradecahydro -1H -cyclopenta [a ] phenanthrene -17 -yl ] acetate (IUPAC)

M03AC09

Template: Infobox chemical / molecular formula search available

Rocuronium is a non- depolarizing muscle relaxant that was introduced in 1995 in Germany in clinical anesthesia. It represents an evolution of the Aminosteroids vecuronium

Properties

Rocuronium has among the non- depolarizing muscle relaxants the shortest onset time ( stop time ) and is therefore the only alternative if it can be used because of contraindications Rapid Sequence Induction in a no succinylcholine. After about 60-90 seconds are good intubation conditions. The clinical duration ( time to 25% spontaneous recovery of control twitch height ) with 0.6 mg · kg -1 rocuronium bromide is 30-40 minutes. The total duration (time until spontaneous recovery to 90 % of control twitch height ) is 50 minutes.

Reduction

It is primarily metabolized in the liver and partly excreted via the kidneys. So be careful with decreased hepatic function.

Application

Like all muscle relaxants rocuronium has no sedative effect and can therefore only be applied under a general anesthetic. It relaxes all muscles, therefore leads the administration of rocuronium for temporary paralysis of the respiratory muscles and apnea. Thus, the application requires the presence of a ventilation option and the presence of an experienced physician in airway management.

Antidote

Since mid-2008 with sugammadex is a specific antidote for rocuronium ( antidotes) are available. By sugammadex the muscle blocking action of rocuronium can be completed within a few minutes, allowing the use of rocuronium during anesthesia discharges with difficult airway management such as RSI ( supra) safer.

Trade names

Esmeron (D, A, CH), as well as a generic (D, A)